[Efficacy and safety of vitamin D for type 2 diabetes mellitus: a systematic review].
To evaluate the efficacy and safety of vitamin D (VD) for patients with type 2 diabetes mellitus. Randomized controlled trials (RCT) were identified from CBM (1978.1-2012.9), CNKI (1979.1-2012.9), Pubmed (1950.1-2012.9), EMbase (1970.1-2012.9) and Cochrane library (issue 4, 2012). Publications of the RCT on the treatment of type 2 diabetes mellitus with VD were included and analyzed according to the criteria of Cochrane handbook. Six RCT involving 328 patients were included. Meta-analysis indicated that VD caused a reduction in glycosylated hemoglobin A 1c (HbA 1c) (P = 0.05) but not in fasting plasma glucose (FPG), homeostasis model assessment index of insulin resistance (HOMA-IR) and failed to improve quantitative insulin sensitivity check index (QUICKI) and homeostasis model assessment index of β cell function (HOMA-β) (P > 0.05). As reported in a trial, the side effect of VD was hypercalcemia. VD may have positive effects on patients with type 2 diabetes mellitus. However, the evidence is weak due to the general low methodological quality. Thus we have not made a reliable conclusion about the effects of VD for type 2 diabetes mellitus at the moment. Further larger, randomized, double-blind, placebo-controlled and multicenter trials are warranted.